India's single-speciality hospital chains are emerging as significant growth engines, driven by increasing patient volumes and aggressive capacity additions in sectors like oncology, paediatrics, and eye care. Companies such as HealthCare Global, Rainbow Children’s Medicare, and Dr Agarwal’s Health Care have reported substantial revenue increases. In contrast, the medical device sector, including firms like Poly Medicure and Tarsons Products, is experiencing slower growth and margin compression due to global conflicts, logistical issues, rising costs, and tariff uncertainties. An EY-Parthenon report indicates that while domestic demand for specialist healthcare remains strong, international factors are creating a more complex operating environment for medical device manufacturers, suggesting a more favorable near-term investment outlook for hospital chains.

India's single-speciality hospital chains are emerging as significant growth engines, driven by increasing patient volumes and aggressive capacity additions in sectors like oncology, paediatrics, and eye care. Companies such as HealthCare Global, Rainbow Children’s Medicare, and Dr Agarwal’s Health Care have reported substantial revenue increases. In contrast, the medical device sector, including firms like Poly Medicure and Tarsons Products, is experiencing slower growth and margin compression due to global conflicts, logistical issues, rising costs, and tariff uncertainties. An EY-Parthenon report indicates that while domestic demand for specialist healthcare remains strong, international factors are creating a more complex operating environment for medical device manufacturers, suggesting a more favorable near-term investment outlook for hospital chains.

India's single-speciality hospital chains are emerging as significant growth engines, driven by increasing patient volumes and aggressive capacity additions in sectors like oncology, paediatrics, and eye care. Companies such as HealthCare Global, Rainbow Children’s Medicare, and Dr Agarwal’s Health Care have reported substantial revenue increases. In contrast, the medical device sector, including firms like Poly Medicure and Tarsons Products, is experiencing slower growth and margin compression due to global conflicts, logistical issues, rising costs, and tariff uncertainties. An EY-Parthenon report indicates that while domestic demand for specialist healthcare remains strong, international factors are creating a more complex operating environment for medical device manufacturers, suggesting a more favorable near-term investment outlook for hospital chains.

India’s single-speciality hospital chains are emerging as quiet growth engines, even as medical device makers navigate a far tougher global environment, according to a just-released EY India health care review for Q4FY26 and FY26.

The report shows oncology, paediatrics, and eye-care platforms continuing to expand at a healthy rate, helped by rising patient volumes, higher-acuity treatments and aggressive capacity additions.

HealthCare Global (HCG), Rainbow Children’s Medicare and Dr Agarwal’s Health Care all reported double-digit revenue growth in FY26, with margins broadly holding up despite expansion-led cost pressures.

HCG, which focuses on oncology, delivered FY26 revenue growth of about 15 per cent, supported by stronger inpatient volumes and a richer case mix across western, southern and eastern India.

This meant that both scale and higher-value procedures had a major hand in sustaining profitability. The chain is now investing in more than 200 additional beds over the next two years in cities such as Bengaluru, Cuttack and Ranchi, signalling continued confidence in specialist cancer care.

Rainbow Children’s Medicare, which operates paediatric and maternity hospitals, continued to expand its footprint with 500 beds added in FY26 and another 900 under execution across Coimbatore, Gurugram, Pune, Bengaluru and Indore.

While Rainbow’s revenue growth is more moderate than some peers, its EBITDA remained stable at 31.5 per cent. This hinted that scale was not costing them operating discipline.

Eye-care group Dr Agarwal’s, meanwhile, posted revenue growth in the low twenties, backed by 57 new greenfield facilities across 14 states and five union territories, and plans for 60 more centres in FY27.

However, medical device companies got the far end of the ward. Poly Medicure and Tarsons Products recorded FY26 revenue growth in the high single to low double digits—well below the mid-teens and above pace seen in leading hospital chains—and significantly weaker EBITDA growth.

The report stressed, “Global conflict has led to logistical disruptions and cost pressures with limited demand impact, resulting in shipment delays and 200–300 bps margin compression.” It also added that “tariff changes caused a temporary US setback but have rationalised in Q4FY26.” This was a testament to how trade policy quickly alters export economics for Indian manufacturers.

For Tarsons, the report linked softer growth to both demand and cost shocks, noting that “overall revenue growth in Q4FY26 was impacted by a 13.4 per cent decline in export business … [and] margins declined due to new facility-related expenses and raw material cost inflation.”

Taken together, the findings suggest that while India’s specialist care platforms are still riding favourable domestic demand, device makers face a more complex mix of US tariff uncertainty, global input-cost inflation and supply-chain disruption.

So, what does this mean for investors? This could signal a clearer near-term earnings runway in single-speciality hospitals, and more patience required on medical devices until global conditions stabilise.

TAGS